The Biden Administration recently announced a plan to leverage an old tool in a new way to try to reduce drug costs: exercising “march-in rights” under the Bayh-Dole Act for drugs that were supported by government funding. ...more
12/20/2023
/ Bayh-Dole Act ,
Biden Administration ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Contractors ,
Federal Trade Commission (FTC) ,
Inflation Reduction Act (IRA) ,
Innovation ,
Intellectual Property Protection ,
Inventions ,
Licenses ,
March-in-Rights ,
National Institute of Health (NIH) ,
NIST ,
Notice of Proposed Rulemaking (NOPR) ,
Orange Book ,
Pharmaceutical Patents ,
Prescription Drugs ,
Public Health Emergency ,
Research and Development
Key Drug Pricing Implications of the Inflation Reduction Act of 2022 -
I. Introduction -
On Sunday, August 7, 2022, the United States Senate passed the most consequential drug and biologics pricing legislation in almost...more
The Department of Health and Human Services (“HHS”) is continuing its focus on women’s health, this time through its research arm, the Agency for Healthcare Research and Quality (“AHRQ”). If the COVID-19 pandemic has shown us...more